SLU-PP-332

SLU-PP-332 is an experimental small molecule studied as an estrogen-related receptor agonist in models of oxidative metabolism, mitochondrial function, exercise adaptation, and energy expenditure.

Reported preclinical work describes activation of estrogen-related receptor transcriptional programs associated with mitochondrial biogenesis and oxidative metabolism.

Early preclinical evidence.

Level V, Early mechanistic research

No established human pharmacokinetic, efficacy, or safety data. It is not a peptide, and capsule presentation strongly implies human consumption.

Human toxicity, receptor selectivity, reproductive effects, carcinogenicity, and long-term metabolic consequences are unknown.

Investigational research chemical; no FDA-approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• SLU-PP-332, 250 mcg × 100Capsule

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.